A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment

• L. Leon-Mateos ^[1] ; M. J. Garcia-Velloso ^[2] ; R. García-Figueiras ^[3] ; J. F. Rodriguez-Moreno ^[4] ; J. L. Vercher-Conejero ^[5] ; M. Sánchez ^[6] ; J. L. Perez Gracia ^[2] ; M. Simo-Perdigo ^[7] ; L. Gorospe ^[8]
  1. [1] Instituto de Investigación Sanitaria de Santiago de Compostela

     Instituto de Investigación Sanitaria de Santiago de Compostela

     Santiago de Compostela, España

     
  2. [2] Universidad de Navarra

     Universidad de Navarra

     Pamplona, España

     
  3. [3] Radiology Department, Hospital Clínico Universitario de Santiago de Compostela
  4. [4] Medical Oncology Department, Centro Integral Oncologico HM Clara Campal, Madrid
  5. [5] Nuclear Medicine Department – PET Unit, Bellvitge University Hospital – IDIBELL
  6. [6] Radiology Department, CDIC, Hospital Clínic, Barcelona
  7. [7] Nuclear Medicine Department, Hospital Universitari Vall Hebron
  8. [8] Radiology Department, Ramón y Cajal University Hospital

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 3 (March), 2021, págs. 434-449
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The implementation of immunotherapy has radically changed the treatment of oncological patients. Currently, immunotherapy is indicated in the treatment of patients with head and neck tumors, melanoma, lung cancer, bladder tumors, colon cancer, cervical cancer, breast cancer, Merkel cell carcinoma, liver cancer, leukemia and lymphomas. However, its efficacy is restricted to a limited number of cases. The challenge is, therefore, to identify which subset of patients would benefit from immunotherapy. To this end, the establishment of immunotherapy response criteria and predictive and prognostic biomarkers is of paramount interest. In this report, a group of experts of the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Medical Radiology (SERAM), and Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) provide an up-to-date review and a consensus guide on these issues.